|
Match
|
Document |
Document Title |
|
|
5015480 |
Film coating formulations
Aqueous diffusion coating formulations suitable for use on pharmaceutical dosage forms comprising an admixture of an insoluble polymer component of a copolymer of ethylacrylate and...
|
|
|
5013728 |
Composition for treating osteoporosis and hormonal imbalance
A medication for providing fluoride ion for the prevention and treatment of bone loss disease, together with an estrogen-containing substance for not only treating hormonal imbalance but to obtain...
|
|
|
5002776 |
Controlled absorption diltiazem formulations
A controlled absorption diltiazem pellet formulation for oral administration comprises a core of diltiazem or a pharmaceutically acceptable salt thereof in association with an organic acid, and a...
|
|
|
4990341 |
Controlled release hydromorphone composition
A solid controlled release, oral dosage form, the dosage form comprising a therapeutically effective amount of hydromorphone or a salt thereof in a matrix wherein the dissolution rate in vitro of...
|
|
|
4968505 |
Long-acting diclofenac sodium preparation
A long-acting diclofenac sodium preparation is disclosed. The preparation comprises a sustained-release diclofenac sodium component which is prepared by coating a sustained-release coat onto a...
|
|
|
4966770 |
Prednisone microencapsulated granules
The invention disclosed is prednisone microencapsulated granules with activity densities greater than about 0.030 g/ml. These granules are unusually small, having diameters less than about 1000...
|
|
|
4965072 |
Granulating composition and method
The invention involves a granulating composition composed of an aqueous solution of magnesium sulfate heptahydrate and sodium hexametaphosphate. This composition can be used to prepare granules of...
|
|
|
4963365 |
Controlled release dosage form
A controlled release dosage form which consists essentially of a core containing a medicament; an inner coating layer composed of ethylcellulose and a hydrophobic substance; and an outer coating...
|
|
|
4959220 |
Antiseptic-containing alginate impression material
An antiseptic-containing alginate impression material contains 0.01 to 7 parts by weight of an antiseptic such as glutaraldehyde and chlorohexydine gluconate per 100 parts by weight of a cured...
|
|
|
4959219 |
Coating barriers comprising ethyl cellulose
Coatings for individual ion exchange resin particles comprised of (a) ethylcellulose and (b) corn oil or acetylated monoglycerides.
|
|
|
4957745 |
Pharmaceutical preparation
Controlled release preparation containing a number of beads comprising a salt of metoprolo as the main soluble component, a method for the production thereof and the use in the treatment of...
|
|
|
4940587 |
Oral pharmaceutical composition through mucosa
An arrangement is provided for the application of an oral pharmaceutical to the mucosa of the oral or nasal cavity, for sustained release there of the drug. The arrangement of the invention...
|
|
|
4938968 |
Controlled release indomethacin
In accordance with the present invention, the controlled release formulation contains coated pellets of indomethacin of only one type. The pellet releases indomethacin in both immediate and...
|
|
|
4927640 |
Controlled release beads having glass or silicon dioxide core
Controlled release preparation containing a number of insoluble beads applied with one or more pharmaceutically active compounds, a method for the production thereof and the use in a treatment...
|
|
|
4919938 |
Sustained release pharmaceutical compositions in oral dosage form
Oral dosage forms for neutral, zwitterions or slats of acidic or basic drugs with approximate zero order release kinetics comprise a core matrix of the drug, and a gelling polymer, the matrix being...
|
|
|
4917899 |
Controlled absorption diltiazem formulation
A diltiazem pellet formulation for oral administration comprises a core of diltiazem or a pharmaceutically acceptable salt thereof in association with an organic acid and a lubricant, and a...
|
|
|
4917900 |
Controlled release formulations containing zidovudine
The invention relates to pharmaceutical formulations comprising discrete units of zidovudine provided with a controlled release coating in which the said units are preferably in the form of spheroids.
|
|
|
4894239 |
Sustained-release preparation and production thereof
The present invention concerns a sustained-release microcapsule preparation comprising an ion exchange resin with 6 to 16% crosslinking, containing a drug adsorbed in an amount not less than 80% of...
|
|
|
4891230 |
Diltiazem formulation
A diltiazem pellet formulation for oral administration comprises a core of diltiazem or a pharmaceutically acceptable salt thereof in association with an organic acid, and a multi-layer membrane...
|
|
|
4888177 |
Pharamaceutical preparations in the form of instant granules or tablets and process for their manufacture
The invention relates to a pharmaceutical preparation that contains at least one pharmaceutically active substance at least one granular carrier material and a layer enveloping the carrier material...
|
|
|
4882169 |
Swellable pellets
Pellets which can be used in liquid oral formulations of drugs are presented. They comprise (a) a core, containing microparticles of at least one pharmaceutically active substance, (b) optionally...
|
|
|
4871549 |
Time-controlled explosion systems and processes for preparing the same
The invention relates to a Time-Controlled Explosion System in which drug release is caused by explosion of a membrane after a definite time period, said System comprising a preparation in the form...
|
|
|
4865851 |
Pharmaceutical composition comprising cefuroxime axetil
Cefuroxime axetil in particulate form is coated with an integral coating of a lipid or mixture of lipids which serves to mask the bitter taste of cefuroxime axetil but disperses or dissolves on...
|
|
|
4863743 |
Controlled release potassium chloride
A controlled release potassium chloride tablet is disclosed which is comprised of potassium chloride crystals having a mesh size of about 30 to about 50 mesh which are coated with a coating...
|
|
|
4861599 |
Galenic formulations for oral use of rhein derivatives with delayed release for therapeutical use
Several methods are disclosed for the preparation of oral pharmaceutical forms with delayed release of rhein and its derivatives. The pharmaceutically active ingredient is provided in the form of...
|
|
|
4859469 |
Novel galenic forms of verapamil, their preparation and medicines containing said novel galenic forms
The invention relates to a novel galenic form of verapamil which show an excellent bioavailability. The novel galenic form comprises microgranules containing a verapamil addition salt with an acid,...
|
|
|
4847077 |
Controlled release pharmaceutical preparations
Controlled release pharmaceutical preparations containing coated sulfonic acid cationic exchange resin drug complex particles, the resin particles having been treated, prior to coating, with about...
|
|
|
4844910 |
Spheroids
A controlled release pharmaceutical composition comprising a plurality of film coated spheroids, the film coated spheroids comprising a 3-alkylxanthine, a non-water soluble spheronising agent and...
|
|
|
4840799 |
Process for preparing rapidly disintegrating granulates
The present invention relates to a process for preparing a rapidly disintegrating core granulate containing a pharmaceutically active compound, which granulate is optionally intended to be coated...
|
|
|
4832955 |
Controlled release potassium chloride composition
The invention is directed to a pharmaceutical composition comprising a microencapsulated potassium salt encapsulated in a shell wall consisting essentially of from about 85% to about 97% ethyl...
|
|
|
4830859 |
Process for lubricating water-soluble vitamin powders
The subject invention relates to a process for preparing lubricated water-soluble vitamin powders. The water-soluble vitamin powders are lubricated by combining them with a lubricant at a...
|
|
|
4816264 |
Sustained release formulations
Drug delivery systems which exhibit sustained release properties when administered are produced using a "dual control" system which employs polymeric agents in core and membrane portions.
|
|
|
4808411 |
Antibiotic-polymer compositions
Compositions which comprise a complex of carbomer (acrylic acid polymers) and erythromycin or a derivative thereof such as 6-O-methylerythromycin, are disclosed. The compositions provide nontoxic,...
|
|
|
4806361 |
Medicaments in sustained release unit dose form
Sustained-release compositions for oral administration comprising medicament-coated nonpareils surrounded by a sustaining coating of at least three admixed polymers afford exceptionally good plasma...
|
|
|
4800084 |
Pharmaceutical product in the form of a pellet with continuous, delayed medicament substance emission
The discovery presented herewith concerns a pharmaceutical product in the form of a pellet with improved continous, delayed medicament substance emission through a coating, which is made of a...
|
|
|
4771077 |
Spray dried acetaminophen
A therapeutic taste-neutral powder form of acetaminophen obtained by spray-drying a suspension of colloidal silica in a lower alkanol solution of acetaminophen and ethyl cellulose.
|
|
|
4754027 |
Process for preparing a product comprising guar-gum
The present invention relates to a process for preparing a product comprising guar-gum present in the form of particles, and possessing a sustained swelling in an aqueous suspension, whereby...
|
|
|
4748023 |
Process for the preparation of sustained release pharmaceutical compositions having a high active ingredient content
The invention relates to a process for the preparation of sustained release solid pharmaceutical compositions having an active ingredient content of at least 80% and possessing a structure which...
|
|
|
4729895 |
Composition for solid pharmaceutical preparations of active vitamins D.sub. 3
This invention is concerned with a composition for solid pharmaceutical preparations of active vitamins D 3 , having the remarkably improved stability of active vitamins D 3 , and an extremely...
|
|
|
4728513 |
Granular delayed-release form of pharmaceutically active substances
A granular delayed-release form of pharmaceutically active substances, which is prepared by coating a granulated or crystalline pharmaceutically active substance, or mixtures thereof, with a...
|
|
|
4675175 |
Coated methionine granules for ruminants
Composition for coating a biologically active substance, which is stable in a medium of which the pH is greater than or equal to 5, and which permits the release of the active substance in a medium...
|
|
|
4656027 |
Pharmaceutical mixture
The present invention is concerned with masking bad taste in pharmaceutical preparations containing encapsulated drugs with bad taste. The object of the invention is achieved by including a basic...
|
|
|
4652442 |
Process of producing a sustained release preparation containing indomethacin or niomethacin
In a process of producing a sustained release preparation containing indomethacin or niomethacin, the active ingredient in the form of a powder as well as one or more food grade substances having a...
|
|
|
4634587 |
Sustained release quinidine dosage form
A sustained release quindine dosage form is made from a plurality of pellets. Each pellet includes a quinidine-containing coating over a nonpareil seed, with a further coating of about 5 to about...
|
|
|
4606940 |
Small particle formation and encapsulation
Process for the formation and the simultaneous encapsulation of small particles of a compound from solution which comprises: (a) dissolving said compound in a first solvent; (b) preparing a...
|
|
|
4540602 |
Process for the preparation of activated pharmaceutical compositions
Disclosed is a process for the preparation of an activated pharmaceutical composition containing a solid drug that is scarcely soluble in water, the pharmaceutical composition being characterized...
|
|
|
4508702 |
Sustained release aspirin
A sustained release aspirin dosage form permits the continuous delivery of aspirin into the gastrointestinal tract for a period of at least eight hours. The sustained release aspirin dosage form...
|
|
|
4490407 |
Method for preparing galenic formulations particularly for pharmaceutical, dietetical, cosmetic and diagnostic uses
A method for preparing a galenic formulation for pharmaceutical, dietetic, cosmetic or diagnostic use, comprising forming a liquid mixture containing at least one active ingredient and at least one...
|
|
|
4486471 |
Process for preparing ethylcellulose microcapsules
Pharmaceutically active compound-containing microcapsules the coating walls of which consist essentially of ethylcellulose and a water-insoluble, acid-soluble polymer material are disclosed. A...
|
|
|
4462982 |
Microcapsules and method of preparing same
Ethylcellulose microcapsules, wherein a polymer material which shows at least 1.2 times increase in weight by immersing it in water at 37° C. is incorporated into the ethylcellulose coating walls...
|